Partial Response News Today

Biodexa Pharmaceuticals PLC announced that results of a Phase 2 clinical trial of eRapa in Familial Adenomatous Polyposis are scheduled for presentation at the prestigious 2024 Digestive Disease...

/PRNewswire/ -- J INTS BIO announced the results of its ongoing Phase 1 clinical study of JIN-A02, a 4th generation EGFR-TKI for NSCLC treatment, at the 8th...

Intermediary results of high dose PDC*lung01 combined with pembrolizumab show mild safety profile, immunological activity and promising tumor response in Non-Small Cell Lung Cancer patientsCombination of high dose PDC*lung01 with pembrolizumab in 19 evaluable patients resulted in objective response rate of 63.2% and...

LIÈGE, Belgium & GRENOBLE, France, April 08, 2024--PDC*line Pharma, a clinical-stage biotech company developing a new class of potent and scalable active immunotherapies for cancers, today announces the interim results from the last cohort of patients in its phase I/II clinical trial (PDC-LUNG-101, NCT03970746) with PDC*lung01.

The farmers protest near the national capital continued despite agreeing to meet central government representatives again on Sunday. Agriculture minister Arjun Munda emphasized the governments desire for a peaceful resolution and prompt conclusion of talks. Talks between farmer union leaders and ministers Piyush Goyal, Nityanand Rai, and Munda in Chandigarh on Friday failed to reach an agreement after a five-hour meeting.

The panel examines the transition from systemic steroids to second-line therapies in chronic GVHD, explore standardized clinical trial definitions and real-world challenges in treating chronic GVHD.

C4 Therapeutics, Inc. presented clinical data from the ongoing Phase 1 dose escalation portion of its Phase 1/2 clinical trial of CFT7455, a MonoDAC?? degrader of IKZF1/3, for the potential treatment...

30.11.2023 - Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today ... Seite 1

Combined Analysis That Includes First Reported Data from Multicohort Phase 2 EBVision Trial Consistent with Previous Single-Center Experience Pooled Analysis Shows 77.8% Objective Response Rate in...

From sleep and neuroendocrine function following TBI to new phase 3 results from a clinical trial evaluating a promising new schizophrenia treatment, here are highlights from the week in Psychiatric Times.